Skip to content

Mometasone vs Budesonide in CRS With Polyposis

Randomized Controled Double-blinded Study Comparing Mometasone Nasal Spray to Budesonide Irrigations in Patients With Chronic Rhinosinusitis With Nasal Polyposis

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03323866
Enrollment
36
Registered
2017-10-27
Start date
2017-05-01
Completion date
2022-08-01
Last updated
2022-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis

Brief summary

The principal objective is to compare the use of mometasone nasal spray to budesonide irrigations in patients suffering from CRSwNP who have never been operated.

Interventions

2 cc nebule of budesonide in 240 cc of saline water (Sinus Rinse) once daily

Mometasone 50 mcg/spray 2 sprays twice daily

Sponsors

Université de Sherbrooke
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Randomized controlled trial comparing mometasone nasal spray to budesonide irrigations for treatment of chronic rhinosinusitis with nasal polyposis

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Diagnosis of chronic rhinosinusitis with nasal polyps * Absence of active infection at start of study

Exclusion criteria

* Diagnosis of chronic rhinosinusitis without nasal polyps * Diagnosis of recurrent acute bacterial rhinosinusitis * Previous sinus surgery (septal of inferior turbinate surgeries are not considered sinus surgeries) * Cystic fibrosis or ciliary dyskinesia * Allergy to corticosteroids * Pregnant or lactating women * Contra-indication to intranasal steroids

Design outcomes

Primary

MeasureTime frameDescription
Disease specific quality of life questionnaire3 months after beginning of treatmentSinoNasal Outcome Test - 22 This is a symptom score ranging from 0 to 110 points, 0 representing the absence of nasal symptoms and 110 being the most severe symptoms.

Secondary

MeasureTime frameDescription
Endoscopic evaluation of the nasal cavities3 months after beginning of treatmentLund Kennedy Endoscopic Score This is a score evaluating the healing of sinonasal cavities from 0 point (normal and healthy looking cavity) to 20 points (the most diseased cavity).

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026